M Ventures
M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, focused on investing in Biotechnology and Technology. The firm targets areas such as Healthcare drug development, Life Science tools, Electronics, and Frontier Technology & Sustainability. M Ventures aims to invest in visionary companies that address challenging diseases, empower scientific research, and develop innovative solutions for information processing and sustainability. The firm takes an active role in its portfolio companies, collaborating with entrepreneurs and co-investors to drive innovation towards commercial success.
M Ventures
Eduard van Beinumstraat 26, 1077 CZ Amsterdam, The Netherlands
Portfolio
Tignis provides AI and ML data science solutions for semiconductor equipment manufacturers.
#Technology
Outrun Therapeutics is an E3 ligase inhibitor company focused on cancer therapeutics.
#Biotechnology
beeOLED is focused on developing efficient and stable deep-blue emitters for OLED displays.
#Technology
LabGenius is pioneering the discovery of next-generation therapeutic antibodies.
#Biotechnology
Akili Interactive develops digital therapeutics, including the FDA-cleared EndeavorRx, a prescription video game for ADHD.
#Digital Medicine
Altoida develops digital biomarkers for neurological diseases using AI and AR.
#Digital Health
Anavo Therapeutics focuses on phosphatase-targeting allosteric modulators for oncology.
#Biotechnology
ApoGen Biotechnologies develops therapeutics targeting cancer genomic mutations.
#Biotechnology
Artios Pharma is a leading DNA Damage Response company developing cancer treatments. Recent developments include the appointment of Professor Rajesh Chopra as Non-Executive Director and the start of a clinical study with its ATR inhibitor, ART0380.
#Biotechnology